BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1198 related articles for article (PubMed ID: 16006865)

  • 1. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
    Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
    Hagiwara H; Sato H; Shirai S; Kobayashi S; Fukumoto K; Ishida T; Seki T; Ariga T; Yano T
    Life Sci; 2006 Apr; 78(19):2249-54. PubMed ID: 16289236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
    Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
    Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
    Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
    Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.